Gsk Q2 Results 2025. On slide 18 is a summary of the group’s results for q2 and the half year. Jemperli (dostarlimab) contributed £25 million ($31 million) in sales in q2, and its growth is being driven by new u.s.

Gsk has generated £1.6bn cash from its operations in the second quarter of 2023, an increase of 3% from the same quarter of 2022. Its vaccine sales saw a boost of.